Flamel Technologies S.A. (ADR) (NASDAQ:FLML)

CAPS Rating: 2 out of 5

A biopharmaceutical company principally engaged in the development of two unique polymer-based drug delivery technologies for the improvement of medical applications.

Results 1 - 20 of 54 : 1 2 3 Next »

Recs

0
Member Avatar pchop12316 (86.65) Submitted: 8/21/2014 2:55:22 PM : Outperform Start Price: $15.57 FLML Score: -6.19

biotech that is gaining momentum upwards

Recs

0
Member Avatar MrMrr (< 20) Submitted: 7/1/2014 10:40:17 AM : Outperform Start Price: $14.88 FLML Score: -3.29

flml is the only one to have this new drug

Recs

0
Member Avatar OKwarrior (32.28) Submitted: 6/9/2014 1:38:50 AM : Underperform Start Price: $12.38 FLML Score: -15.91

declining revenues, negative cash flows. Not going to outpace the market.

Recs

1
Member Avatar d3ming (40.64) Submitted: 6/4/2014 1:16:16 PM : Outperform Start Price: $11.11 FLML Score: +28.34

#zzporte

Recs

1
Member Avatar phatchips767 (< 20) Submitted: 2/25/2014 5:34:00 PM : Outperform Start Price: $13.17 FLML Score: +2.57

french company. portofeille likeded em

Recs

1
Member Avatar ihletrader (< 20) Submitted: 1/22/2014 10:34:12 AM : Outperform Start Price: $10.33 FLML Score: +33.32

good perspective shared by ZZ.

Recs

7
Member Avatar zzlangerhans (99.77) Submitted: 1/21/2014 8:57:19 PM : Outperform Start Price: $10.34 FLML Score: +32.92

Every now and then I wonder if I really have to follow 250 stocks to succeed in trading biopharma. Life would be a lot easier if I chucked out half those stocks that I thought I would never trade and just focused on the more high yield players. Then again, one of the first stocks I would have cut from my database would have been Flamel, a weird and murky company whose pipeline of controlled-release therapeutics I've never understood. I've just played with the stock on CAPS, placing red thumbs or green thumbs whenever the stock strayed out of trading range and doing fairly well with that.

In 2012 Flamel acquired Eclat Pharmaceuticals, which I didn't pay a lot of notice to since it seemed typical of the kind of chickenfeed deals small pharmas do when the assets they already have don't seem to be going anywhere. I did note that the CEO of Eclat took over the CEO job at Flamel, indicating it was a kind of reverse merger. Nevertheless, when Flamel abruptly announced they were submitting an NDA for an undisclosed product in late 2012 I didn't make the connection with Eclat. In June I learned that the NDA was for a branded form of grandfathered generic anesthesiology drug neostigmine for reversal of intra-operative muscle paralysis. Huh? What's the point of getting a drug approved to compete with cheap generics that have been available for more than fifty years?

In September the FDA accepted a second NDA for an undisclosed compound with a PDUFA of April 28, 2014. I still didn't get what was going on until I recently reviewed the stock and read a couple of Seeking Alpha articles by a chiropractor named Ronny Hyman. Even though I can't stand Seeking Alpha and most of the touts who write optimistic articles about stocks therein, I do try to keep an open mind and I found this guy to have a coherent, well-researched thesis. Basically, Eclat is pursuing approval of these old generic drugs to take advantage of a federal program called DESI, designed to replace the grandfathered generics with new standardized drugs approved through the formal FDA process. Part of the approval process is a requirement for the generic manufacturers to remove their versions of the drug from the markets. Two of three producers of generic neostigmine have already done so, and the third is expected to do so shortly.

Flamel's branded neostigmine probably won't be able to maintain market exclusivity for more than a few years, but as I mentioned previously they have another DESI product pending approval in April and several more in the pipeline. Optimism over revenues for this drug has certainly been the basis for a doubling of share price in recent months and there's a good chance the upward momentum will continue. In accordance with my resolution to go against my aversion to buying biopharma stocks well off their lows, I purchased 1000 shares for the zzporte portfolio at 10.85 and expect to purchase another 1000 shares at some point in the near future barring any unexpected developments.

Recs

0
Member Avatar line70day (< 20) Submitted: 10/28/2013 3:13:51 PM : Outperform Start Price: $7.24 FLML Score: +92.26

2nd Q FDA approved NDA first approval for drugs that will be 100% controlled by Flamel This is first filling that came out of Eclat's pipeline 3 more products steadly advancing

Recs

0
Member Avatar KimLanners (< 20) Submitted: 4/24/2011 2:15:52 AM : Outperform Start Price: $6.20 FLML Score: +86.83

nanobiotech good technicals

Recs

0
Member Avatar face2thehighfog (79.87) Submitted: 9/18/2009 10:38:47 AM : Outperform Start Price: $9.55 FLML Score: -33.37

nano!

Recs

0
Member Avatar AAAAmanda (51.30) Submitted: 2/2/2009 2:37:12 PM : Outperform Start Price: $4.19 FLML Score: +103.41

5.1172 at $111.00 or 21.69 per share. Can't do much worse.

Recs

0
Member Avatar zoiebelle (47.73) Submitted: 6/4/2008 10:10:50 PM : Outperform Start Price: $10.45 FLML Score: -8.66

Niche in medical technology will pay off.

Recs

0
Member Avatar WERDOSD44 (79.31) Submitted: 3/24/2008 4:17:03 PM : Outperform Start Price: $8.96 FLML Score: +10.51

THIS STOCK HAS BEEN AT $31.96, BELIEVE ITS ON ITS WAY TO THAT AREA AGAIN

Recs

0
Member Avatar gdufour (40.60) Submitted: 1/16/2008 5:50:39 AM : Outperform Start Price: $9.40 FLML Score: +4.86

Never stays above 30, but surely gets there every now and then, so at a price below 10, this is a good bargain.

Recs

0
Member Avatar nmhiplains (66.48) Submitted: 1/14/2008 10:07:03 PM : Outperform Start Price: $9.54 FLML Score: +5.20

Drug release procall for insulin

Recs

0
Member Avatar taryntoo (< 20) Submitted: 12/26/2007 12:14:19 AM : Outperform Start Price: $10.70 FLML Score: -2.67

Bought at the bottom of their 52 week range. Not sure even that price is justified, but hoping their delivery technology will find new markets.

Recs

0
Member Avatar PicoTrader (< 20) Submitted: 10/19/2007 1:14:42 PM : Outperform Start Price: $8.15 FLML Score: +42.45

purely a play on the fallen who should get up, even if its to a crawling position....

Recs

0
Member Avatar lowmaple (69.43) Submitted: 10/19/2007 2:01:20 AM : Outperform Start Price: $9.10 FLML Score: +24.96

rebound

Recs

0
Member Avatar scrubs620 (< 20) Submitted: 9/12/2007 8:01:25 PM : Outperform Start Price: $9.95 FLML Score: +6.22

New license with Wyeth for the use of its protein delivery system.

Recs

0
Member Avatar miralooku (53.36) Submitted: 9/8/2007 5:55:35 AM : Outperform Start Price: $9.14 FLML Score: +17.41

Powerful technology, activist investors, and 52-low price adds up to a market over-reaction. Buy now sit back, and enjoy the ride. This will return at least 50% in the next year or so.

Results 1 - 20 of 54 : 1 2 3 Next »

Featured Broker Partners


Advertisement